Misfolding and aggregation of proteins containing expanded polyglutamine repeats underlie Huntington's disease and other neurodegenerative disorders 1 . Here, we show that the heterooligomeric chaperonin TRiC (also known as CCT) physically interacts with polyglutamine-expanded variants of huntingtin (Htt) and effectively inhibits their aggregation. Depletion of TRiC enhances polyglutamine aggregation in yeast and mammalian cells. Conversely, overexpression of a single TRiC subunit, CCT1, is sufficient to remodel Htt-aggregate morphology in vivo and in vitro, and reduces Htt-induced toxicity in neuronal cells. Because TRiC acts during de novo protein biogenesis 2 , this chaperonin may have an early role preventing Htt access to pathogenic conformations. Based on the specificity of the Htt-CCT1 interaction, the CCT1 substrate-binding domain may provide a versatile scaffold for therapeutic inhibitors of neurodegenerative disease.Late-onset neurodegenerative diseases are often associated with the accumulation of insoluble amyloid aggregates in neurons 3 . In many cases, such as spinocerebellar ataxia and Huntington's disease, aggregation is associated with expanded polyglutamine (polyQ) tracts in the disease gene, usually beyond a critical threshold of approximately 40 glutamine repeats 1 . Because polyQ disease proteins are the main aggregate component in affected neurons 4 , and glutamine tract length correlates with both aggregation propensity and age of onset of disease, it seems that toxic conformations of the polyQ-expanded proteins are directly responsible for neuronal dysfunction and death 1,5 .Recent studies suggest that the age-dependent accumulation of protein aggregates in neurodegenerative diseases reflects the progressive inability of the cellular quality control machinery to recognize and eliminate potentially toxic conformations. Molecular chaperones, which selectively bind non-native proteins and facilitate their folding or degradation 6,7 , have been shown to modulate aggregation and toxicity in neurodegenerative disease models. In particular, overexpression studies have demonstrated that the chaperone Hsp70 and its cofactors, such as Hsp40, can remodel polyQ aggregates and alleviate the toxicity of polyQ aggregation 4 . Although these studies establish a role for chaperones in modulating polyQ aggregation, the chaperones that normally interact with pathogenic polyQ conformations and 3Correspondence should be addressed to J.F. (jfrydman@stanford.edu).